AngioDynamics’ (ANGO) Buy Rating Reiterated at HC Wainwright

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $14.00 price objective on the medical instruments supplier’s stock. HC Wainwright’s target price indicates a potential upside of 85.68% from the stock’s previous close.

Separately, Canaccord Genuity Group reduced their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average price target of $12.25.

AngioDynamics Trading Down 2.1 %

Shares of ANGO stock opened at $7.54 on Friday. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $8.25. The stock has a market cap of $302.01 million, a price-to-earnings ratio of -1.56 and a beta of 0.65. The company’s 50-day moving average price is $7.45 and its 200-day moving average price is $6.51.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.11. The business had revenue of $71.00 million during the quarter, compared to analysts’ expectations of $70.86 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The business’s revenue for the quarter was down 22.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.02 EPS. As a group, equities research analysts predict that AngioDynamics will post -0.41 EPS for the current year.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in the stock. Quarry LP raised its position in AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares during the period. Systematic Financial Management LP raised its holdings in shares of AngioDynamics by 8.4% in the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after buying an additional 162,972 shares during the period. Mackenzie Financial Corp acquired a new position in AngioDynamics during the 2nd quarter worth about $80,000. Millennium Management LLC lifted its stake in AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after acquiring an additional 529,861 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its holdings in AngioDynamics by 135.1% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 109,536 shares of the medical instruments supplier’s stock valued at $663,000 after acquiring an additional 62,945 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.